XUHC:XETRA:XETRA-Xtrackers MSCI USA Health Care UCITS ETF 1D (EUR)

ETF | Others |

Last Closing

USD 55.99

Change

+0.55 (+0.99)%

Market Cap

USD 0.85B

Volume

3.31K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.41 (+0.79%)

USD 501.76B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.13 (+0.77%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.26 (+0.97%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.21 (+0.73%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.10 (+0.41%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

+0.02 (+0.01%)

USD 101.19B
JARI:XETRA Amundi Index Solutions - Amund..

+0.01 (+0.01%)

USD 100.74B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.40 (+0.78%)

USD 85.64B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.19 (+0.20%)

USD 84.07B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+1.48 (+0.27%)

USD 80.38B

ETFs Containing XUHC:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.10% 63% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.10% 62% D 62% D
Trailing 12 Months  
Capital Gain 14.31% 42% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.31% 42% F 45% F
Trailing 5 Years  
Capital Gain 75.22% 82% B 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.22% 82% B 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 10.69% N/A N/A 71% C-
Dividend Return 10.77% N/A N/A 70% C-
Total Return 0.07% N/A N/A 3% F
Risk Return Profile  
Volatility (Standard Deviation) 10.67% N/A N/A 66% D+
Risk Adjusted Return 100.91% N/A N/A 96% N/A
Market Capitalization 0.85B 75% C 66% D+

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike